Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -133,969 | -176,353 | -114,347 | -53,836 | 205,819 |
| Depreciation Amortization | 53,082 | 41,913 | 48,804 | 39,082 | 32,190 |
| Income taxes - deferred | -25,617 | -8,905 | -9,921 | 4,363 | -230,577 |
| Accounts receivable | -25,951 | -8,740 | -4,227 | -18,456 | -13,036 |
| Other Working Capital | -15,884 | -8,100 | 33,059 | -25,437 | -42,093 |
| Other Operating Activity | 77,917 | 102,850 | 64,241 | 72,699 | 66,443 |
| Operating Cash Flow | $-70,422 | $-57,335 | $17,609 | $18,415 | $18,746 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 301,277 | -106,399 | -144,331 | 66,562 | -15,298 |
| PPE Investments | -117,062 | -181,693 | -44,571 | -73,219 | -49,461 |
| Net Acquisitions | N/A | -9,875 | N/A | N/A | -32,950 |
| Purchase Of Investment | N/A | N/A | -1,743 | -1,903 | -3,633 |
| Purchase Sale Intangibles | 67,500 | N/A | 0 | -81,000 | 0 |
| Other Investing Activity | 12,112 | -885 | -5,000 | -81,000 | 0 |
| Investing Cash Flow | $196,327 | $-298,852 | $-195,645 | $-89,560 | $-101,342 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 726,202 | 0 | 0 | N/A |
| Debt Repayment | N/A | N/A | N/A | -879 | -195 |
| Common Stock Issued | 197,368 | 72,579 | 318,560 | 33,592 | 33,103 |
| Common Stock Repurchased | N/A | -29,813 | 0 | 0 | N/A |
| Other Financing Activity | -13,170 | -22,297 | -6,269 | -3,375 | -29,404 |
| Financing Cash Flow | $184,198 | $746,671 | $312,291 | $29,338 | $3,504 |
| Exchange Rate Effect | -3,398 | -2,230 | N/A | N/A | N/A |
| Beginning Cash Position | 568,781 | 180,527 | 46,272 | 88,079 | 167,171 |
| End Cash Position | 875,486 | 568,781 | 180,527 | 46,272 | 88,079 |
| Net Cash Flow | $306,705 | $388,254 | $134,255 | $-41,807 | $-79,092 |
| Free Cash Flow | |||||
| Operating Cash Flow | -70,422 | -57,335 | 17,609 | 18,415 | 18,746 |
| Capital Expenditure | -117,062 | -181,693 | -44,571 | -73,219 | -49,461 |
| Free Cash Flow | -187,484 | -239,028 | -26,962 | -54,804 | -30,715 |